--- title: "The 3 Best Brain-Computer Interface Stocks to Buy Now" description: "The global market for brain-computer interface (BCI) technology is expected to grow at a CAGR of 17.5% to reach $6.2 billion by 2030. This technology has various applications in industries like biotec" type: "news" locale: "en" url: "https://longbridge.com/en/news/209997100.md" published_at: "2024-07-27T13:00:00.000Z" --- # The 3 Best Brain-Computer Interface Stocks to Buy Now > The global market for brain-computer interface (BCI) technology is expected to grow at a CAGR of 17.5% to reach $6.2 billion by 2030. This technology has various applications in industries like biotechnology, medical research, mental wellness, and gaming. Three promising BCI stocks to consider are Clearpoint Neuro Inc (CLPT), Snap Inc (SNAP), and Integra Lifesciences (IART). These companies show potential for growth and innovation in the BCI sector. Brain-computer interface (**BCI**) technology creates a direct link between the brain’s electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functions. Forecasts predict global BCI market growth rallying at a compound annual growth rate (**CAGR**) of 17.5% to a value of $6.2 billion by 2030. The emergence of new use cases will drive the sector forward over the coming years. Brain-computer interfaces have a number of purposes. They can be used to great effect in industries like biotechnology, medical research, mental wellness and even gaming. Indeed, medical technology firms grew at a significant pace on Wall Street in the wake of Covid-19. Yet, many leading stocks have struggled to maintain momentum. Simultaneously, the generative artificial intelligence (**AI**) boom has captured the imagination of investors of all scales. However, the number of U.S. citizens aged 65 and above grew to 55.8 million, as of the 2020 census. Thus, the nation’s aging population is likely to lead to a more widespread adoption of medical technology. Investors could see brain-computer interface stocks accelerate in value as long-term holds. In this scenario, key stock market considerations include these three best brain-computer interface stocks. ## **Clearpoint Neuro Inc (CLPT)** Source: Panuwach/Shutterstock When it comes to biotechnology, **Clearpoint Neuro Inc** (NASDAQ:**CLPT**) has built a strong presence in the field of cell and gene therapy, focusing on navigation to the brain and spine. With a market capitalization of over $200 million, a collective of more than 50 partners in biologics and drug delivery, and over 75 neurosurgery centers globally, the company is well-positioned to grow into an industry that’s still emerging. Clearpoint hasn’t been profitable in the past 12 months. Yet this doesn’t appear to faze investors, who have pushed the stock more than 40% higher in July alone. Zooming out, CLPT has grown 16.87% in the last year, but still sits almost 95% below its all-time high market value back in 2012. This suggests the firm has plenty of room for growth, and judging by the firm’s positive movements in drug delivery and the prospect of new services added to the mix, we could see the stock mount a challenge to recover its former glories in the more long-term future. ## **Snap Inc (SNAP)** Source: BigTunaOnline / Shutterstock Former social media giant and current tech innovator, **Snap Inc** (NYSE:**SNAP**) is certainly an unconventional brain-computer interface company to consider. But there may be no better option for portfolios in terms of growth prospects. In terms of performance, Snap ended Q2 of fiscal year 2024 80% adrift from its post-pandemic market high recorded in September 2021. However, the likes of **Morgan Stanley** (NYSE:**MS**) have recently upgraded their price predictions for the stock from $12 to $15 based on improving ad performance for the company. However, Snap’s long-term sustainability is driven by its movements in strategic acquisitions. In 2022, the tech firm acquired NextMind, a French startup that’s best known for its BCI controller, which uses brain signals to move images on a PC interface. As a key player in virtual reality (**VR**) and augmented reality (**AR**) technology, the utility of brain-computer interface technology in the field of gaming could be a pioneering move for SNAP. ## **Integra Lifesciences (IART)** Source: shutterstock.com/cono0430 One example of a stock that’s been making waves in BCI technology for many years in **Integra Lifesciences** (NASDAQ:**IART**). It initially went public in 1995 and debuted brain mapping software as a treatment for Parkinson’s Disease in 2007. Like many medically-focused stocks, Integra Lifesciences has struggled to build on the momentum generated in 2021. Currently, it sits more than 50% below its post-pandemic highs. Despite this, there have been plenty of positive market movements for the medical device manufacturer, and in July IART announced that it plans to have a state-of-the-art facility operational in Braintree, Massachusetts by the first half of 2026. The first quarter of 2024 has also seen the State Board of Administration of Florida Retirement System increase its stake by 18.6% in IART, increasing its holdings in the company to a value of $2,893,000. With a long and rich history in brain-computer interface technology, Integra Lifesciences has the potential to leap to the forefront of the industry’s emergence in the fields of biotech and the many other industries that could benefit from the implementation of BCI tools. With this in mind, the stock could be a strong speculative option for investors. *On the date of publication, Dmytro Spilka did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.* *On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.* Dmytro is a finance and investing writer based in London. He is also the founder of Solvid, Pridicto and Coinprompter. His work has been published in Nasdaq, Kiplinger, FXStreet, Entrepreneur, VentureBeat and InvestmentWeek. Artificial Intelligence, Biotech, Healthcare, Software, Technology, Video Games ### Related Stocks - [IART.US - Integra LifeSciences](https://longbridge.com/en/quote/IART.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 根據 Allied Market Research 的數據，全球再生醫學市場預計到 2033 年將達到 5317 億美元，年複合增長率為 32.4% | 再生醫學市場預計將從 2023 年的 321 億美元增長到 2033 年的 5317 億美元，年均增長率為 32.4%。主要驅動因素包括慢性疾病的增加和老齡化人口，而高昂的治療費用則構成挑戰。細胞治療領域在收入上領先，腫瘤學應用也十分顯著。 | [Link](https://longbridge.com/en/news/275491152.md) | | FDA 因感染風險對英特格拉傷口護理產品發佈警告 | 美國食品藥品監督管理局（FDA）已發佈警報，警告與英特格拉生命科學（Integra LifeSciences）某些傷口和燒傷護理產品相關的潛在感染風險。該警報強調了可能影響無菌性的包裝和生產缺陷。受影響的產品包括 MediHoney 傷口和 | [Link](https://longbridge.com/en/news/273543037.md) | | FDA 表示英特格拉生命科學發現了與 Medihoney 傷口和燒傷產品及 CVS 傷口凝膠產品相關的包裝缺陷 | 美國食品藥品監督管理局（FDA）報告稱，英特格拉生命科學在 Medihoney 傷口和燒傷產品中發現了包裝缺陷，這可能會影響無菌屏障。此外，在某些西維斯傷口凝膠產品中發現了生產和過程控制問題。截至 2025 年 12 月 19 日，已有 1 | [Link](https://longbridge.com/en/news/273412120.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.